The growing popularity of weight loss drugs such as Ozempic and Wegoby is revolutionizing the food and healthcare industries.
Weight-loss drugs are being blamed for the decline in demand for foods linked to weight gain: Morgan Stanley analysts estimate that U.S. consumption of soda, baked goods, and savory snacks could fall by up to 3% by 2035.
These drugs are also changing the food and dietary supplement industry as people seek solutions to the undesirable cosmetic effects of rapid weight loss.
One of these conditions is the so-called “Ozempic face”, characterised by sunken cheeks and eyes and deep facial wrinkles, and there is now a growing demand for healthcare products to address this cosmetic issue.
One of the companies at the forefront of this growing market is Nestlé Health Science, a subsidiary of Swiss multinational food and beverage company Nestlé SA, which has been the world’s largest publicly traded food company by revenue since 2014.
Nestlé Health Science has emerged as a pioneer in this evolving landscape with the launch of an initiative called “GLP-1 Nutrition” aimed at supporting consumers on their weight loss journey.
Nestlé Health Science GLP-1 Nutrition Initiative
The GLP-1 Nutrition Platform provides extensive nutritional guidance and customized products to address the unique challenges faced by users of weight loss drugs by offering a range of products including collagen peptides to enhance skin elasticity.
